Literature DB >> 2597208

Interleukin-1-inhibitory IgG in sera from some patients with rheumatoid arthritis.

H Suzuki1, T Akama, M Okane, I Kono, Y Matsui, K Yamane, H Kashiwagi.   

Abstract

Inhibition of interleukin-1 alpha (IL-1 alpha) activity was detected in 7 of 41 serum samples from patients with rheumatoid arthritis (RA). These 7 sera inhibited not only IL-1 alpha-induced endothelial cell adherence to neutrophils, but also IL-1 beta-induced endothelial cell adherence, although to a lesser extent. These sera showed no influence on tumor necrosis factor-induced endothelial cell adherence. No inhibitory activity was found in 40 sera from normal control subjects. Studies to further examine these effects included gel filtration analysis of 2 of the RA sera. The inhibitory activity was eluted near Mr 158 kd and above Mr 250 kd. Analysis by protein A affinity chromatography showed that IL-1-inhibitory activity was present in protein A-binding fractions. Purified IgG (by DE-52 column chromatography) from RA patients was found to be as potent an inhibitor as the protein A-binding fractions, which suggests that the major inhibitory activity in RA sera is attributable to IgG molecules. These purified IgG molecules also inhibited IL-1-induced proliferation of mouse thymocytes but did not influence IL-2-dependent proliferation of the CTLL-2 murine T cell line. The 7 patients whose sera showed IL-1-inhibitory activity had mild RA and low titers of rheumatoid factor. The findings, taken together, suggest a possible regulatory role of IL-1-inhibitory IgG in RA disease activity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2597208     DOI: 10.1002/anr.1780321206

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  8 in total

1.  An experimental study of the neurogenic and the immunological contribution to "tennis elbow" in rats.

Authors:  E Haker; E Theodorsson; T Lundeberg
Journal:  Inflammation       Date:  1997-02       Impact factor: 4.092

2.  Increased incidence of neutralizing autoantibodies against interleukin-1 alpha (IL-1 alpha) in nondestructive chronic polyarthritis.

Authors:  P Jouvenne; F Fossiez; P Garrone; O Djossou; J Banchereau; P Miossec
Journal:  J Clin Immunol       Date:  1996-09       Impact factor: 8.317

3.  Detection of autoantibodies to cytokines.

Authors:  K Bendtzen; M B Hansen; C Ross; M Svenson
Journal:  Mol Biotechnol       Date:  2000-03       Impact factor: 2.695

4.  Human neutrophil activating peptide/interleukin 8 acts as an autoantigen in rheumatoid arthritis.

Authors:  P Peichl; M Ceska; H Broell; F Effenberger; I J Lindley
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

5.  Binding of cytokines to pharmaceutically prepared human immunoglobulin.

Authors:  M Svenson; M B Hansen; K Bendtzen
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

6.  Autoantibodies against interleukin 1alpha in rheumatoid arthritis: association with long term radiographic outcome.

Authors:  N A Graudal; M Svenson; U Tarp; P Garred; A-G Jurik; K Bendtzen
Journal:  Ann Rheum Dis       Date:  2002-07       Impact factor: 19.103

7.  Anti-IL-1 alpha autoantibodies in patients with rheumatic diseases and in healthy subjects.

Authors:  H Suzuki; T Ayabe; J Kamimura; H Kashiwagi
Journal:  Clin Exp Immunol       Date:  1991-09       Impact factor: 4.330

Review 8.  Pre-existing Antibody: Biotherapeutic Modality-Based Review.

Authors:  Boris Gorovits; Adrienne Clements-Egan; Mary Birchler; Meina Liang; Heather Myler; Kun Peng; Shobha Purushothama; Manoj Rajadhyaksha; Laura Salazar-Fontana; Crystal Sung; Li Xue
Journal:  AAPS J       Date:  2016-01-28       Impact factor: 4.009

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.